Entos Pharmaceuticals Laboratory (IMAGE)
Caption
Entos is developing Covigenix, a pan-coronavirus DNA vaccine based on its Fusogenix drug delivery technology. EpiVax will provide optimized epitopes from multiple COVID-19 proteins identified using their proprietary in silico immunogenicity screening technology.
Credit
Michael Wong
Usage Restrictions
None
License
Licensed content